TNF Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Recent Developments, Liquidity and Management???s Plans (Details Narrative)

Recent Developments, Liquidity and Management’s Plans (Details Narrative) - USD ($)			3 Months Ended						9 Months Ended		12 Months Ended
	Apr. 16, 2022	Apr. 16, 2021	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Aug. 17, 2022	Dec. 31, 2020	Mar. 23, 2020
Goodwill			$ 10,498,539						$ 10,498,539		$ 10,498,539
Fair market value price per share												$ 4.25
Cash on hand			309,926						309,926		555,967
Marketable securities			6,774,381						6,774,381		11,003,071
Loss from operations			3,693,741			$ 5,467,281			11,451,818	$ 26,649,321
Working capital			6,296,506						6,296,506
Stockholders' equity			18,327,047	$ 16,118,343	$ 19,622,140	25,891,924	$ 31,074,335	$ (8,346,738)	18,327,047	25,891,924	23,647,174		$ (5,257,034)
Accumulated deficit			90,013,386						90,013,386		78,561,568
Net cash provided by operating activities									10,021,664	14,704,008
Net loss			3,693,741	$ 3,636,043	$ 4,122,034	5,467,281	$ 18,092,336	$ 3,089,704	11,451,818	26,649,321
Non cash share based compensation			$ 352,417						581,663	15,036,051
Increase in trade and other payables									$ 730,683	$ (3,234,057)
Restricted Stock Units (RSUs) [Member]
Non cash share based compensation		$ 979,758
Contribution Agreement [Member] \| Premas Biotech PVT Ltd [Member]
Amount owed on investments											1,500,000
Payments to investments											$ 1,200,000
Merger Agreement [Member]
Issuance of post reverse stock split		28,553,307
Exchange ratio percentage		77.05%
Percentage of common stock	49.68%
Merger Agreement [Member] \| Pre-funded Warrants [Member]
Warrants to purchase		986,486
Cystron Biotech LLC [Member] \| Membership Interest Purchase Agreement [Member]
Acquired membership interests, percentage														100.00%
MYMD Pharmaceuticals, Inc., [Member] \| Merger Agreement [Member]
Business acquisition description		Upon completion of the Merger and the transactions contemplated in the Merger Agreement, the Company issued 28,553,307 post reverse stock split shares of Company Common Stock to the former stakeholders of pre-Merger MyMD Florida at the Exchange Ratio. Upon completion of the Merger and the transactions contemplated in the Merger Agreement, the former stakeholders of pre-Merger MyMD Florida held approximately 77.05% of the Company’s Common Stock outstanding on a fully diluted basis, assuming the exercise in full of the pre-funded warrants to purchase 986,486 shares of Company Common Stock and including 4,188,315 shares of Company Common Stock underlying options to purchase shares of pre-Merger MyMD Florida Common Stock assumed by the company at closing and after adjustments based on the Company’s net cash at closing. Holders of pre-Merger common stock of the Company held approximately 22.95% of the outstanding equity of the Company. Also upon completion of the Merger and the transactions contemplated by the Merger Agreement, the Company assumed 4,188,315 MyMD Florida stock options subject to certain terms contained in the Merger Agreement (including, but not limited to, the amendment of such stock option to extend the term of such stock option for a period expiring on April 16, 2023, the second-year anniversary of the Merger
Akers Biosciences, Inc [Member]
Goodwill		$ 10,498,539
Pre market capitalization		42,477,346
Tangible asset		$ 31,978,807
Common shares outstanding		8,335,627
Akers Biosciences, Inc [Member] \| Restricted Stock Units (RSUs) [Member]
Vested restricted stock unit		263,026
Fair market value price per share		$ 4.94